Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Crispr Therapeutics AG

Healthcare US CRSP

52.08USD
0.06(0.12%)

Last update at 2026-06-03T20:16:00Z

Day Range

50.5252.28
LowHigh

52 Week Range

33.0378.48
LowHigh

Fundamentals

  • Previous Close 52.02
  • Market Cap5331.02M
  • Volume1269302
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-548.83898M
  • Revenue TTM3.51M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -494.77600M
  • Diluted EPS TTM-6.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -577.96500M -362.66500M -150.72200M -650.50000M 379.53M
Minority interest - - - - -
Net income -581.59900M -366.25200M -153.61000M -650.17500M 377.66M
Selling general administrative 73.54M 72.98M 76.16M 102.46M 102.80M
Selling and marketing expenses - - - - -
Gross profit -229.44900M -75.25000M 239.75M -109.81400M 913.08M
Reconciled depreciation 19.48M 19.26M 19.84M 24.17M 17.95M
Ebit -568.31800M -466.56600M -222.53800M -697.33300M 355.57M
Ebitda -548.83900M -447.30700M -202.70100M -673.16100M 373.53M
Depreciation and amortization 19.48M 19.26M 19.84M 24.17M 17.95M
Non operating income net other - - - 22.66M 6.00M
Operating income -568.31800M -466.56600M -222.53800M -673.16100M 373.53M
Other operating expenses 571.83M 501.57M 592.54M 673.60M 539.55M
Interest expense - - - -46.83300M 23.96M
Tax provision 3.63M 3.59M 2.89M -0.32500M 1.87M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.63M 3.59M 2.89M -0.32500M 1.87M
Total revenue 3.51M 35.00M 370.00M 0.44M 913.08M
Total operating expenses 338.87M 391.32M 462.29M 563.35M 539.55M
Cost of revenue 232.96M 110.25M 130.25M 110.25M -
Total other income expense net -9.64700M 103.90M 71.82M 22.66M 6.00M
Discontinued operations - - - - -
Net income from continuing ops -581.59900M -366.25200M -153.61000M -650.17500M 377.66M
Net income applicable to common shares - - - -650.17500M 377.66M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2265.24M 2242.03M 2229.57M 2243.06M 2751.88M
Intangible assets - - 0.02M 0.07M 0.12M
Earning assets - - - - -
Other current assets 9.84M 8.31M 14.39M 37.71M 38.08M
Total liab 343.43M 309.95M 346.77M 367.58M 352.42M
Total stockholder equity 1921.81M 1932.08M 1882.80M 1875.48M 2399.46M
Deferred long term liab - - - - -
Other current liab 103.63M 51.49M 50.91M 65.51M 91.90M
Common stock 3.09M 2.70M 2.50M 2.44M 2.39M
Capital stock 3.09M 2.70M 2.50M 2.44M 2.39M
Retained earnings -1947.55100M -1365.95200M -999.70000M -846.09000M -195.91500M
Other liab - - - 18.29M 19.66M
Good will - - - - -
Other assets - - - 16.27M 22.20M
Cash 355.19M 298.26M 389.48M 211.88M 923.03M
Cash and equivalents - - - - -
Total current liabilities 149.12M 87.78M 108.79M 121.11M 119.88M
Current deferred revenue 15.77M 3.85M 4.11M 12.32M 1.01M
Net debt 39.73M -74.56400M -150.84500M 32.14M -698.00100M
Short term debt 18.58M 17.29M 15.62M 15.84M 12.16M
Short long term debt - - - - -
Short long term debt total 394.91M 223.69M 238.63M 244.02M 225.03M
Other stockholder equity 3861.46M 3293.49M 2878.09M 2734.78M 2598.05M
Property plant equipment - - - 163.63M 137.57M
Total current assets 1985.67M 1937.13M 1908.08M 1853.03M 2417.51M
Long term investments - 0.00000M 1.97M 53.13M -
Net tangible assets - - - 1875.48M 2399.46M
Short term investments 1628.27M 1605.57M 1304.21M 1603.43M 1456.10M
Net receivables 0.00000M 25.00M 200.00M 4.64M 0.30M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 11.14M 14.71M 38.15M 27.43M 14.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 4.82M 1.84M 1.91M -15.64700M -5.06700M
Additional paid in capital - - - - -
Common stock total equity - - - 2.44M 2.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -846.09000M -195.91500M
Treasury stock - - - -0.06300M -0.06300M
Accumulated amortization - - - - -
Non currrent assets other 32.00M 27.35M 13.57M 16.27M 22.20M
Deferred long term asset charges - - - - -
Non current assets total 279.57M 304.90M 321.49M 390.03M 334.36M
Capital lease obligations 206.75M 223.69M 238.63M 244.02M 225.03M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -5.89100M -280.48100M 280.57M -258.65500M -953.72500M
Change to liabilities - - - 3.64M 32.21M
Total cashflows from investing activities -31.80500M -280.48100M 374.65M -258.65500M -1035.43000M
Net borrowings - - - - -
Total cash from financing activities 426.03M 331.98M 62.66M 38.59M 250.94M
Change to operating activities - - - 15.39M -9.71100M
Net income -581.59900M -366.25200M -153.61000M -650.17500M 377.66M
Change in cash 49.30M -91.29200M 177.59M -715.88400M -245.52400M
Begin period cash flow 309.78M 401.07M 211.88M 939.94M 1185.47M
End period cash flow 359.08M 309.78M 389.48M 224.06M 939.94M
Total cash from operating activities -345.01400M -142.77400M -260.37500M -495.74100M 538.97M
Issuance of capital stock 398.09M 300.69M 32.72M 0.97M 213.27M
Depreciation 19.48M 19.26M 19.84M 24.17M 17.95M
Other cashflows from investing activities -33.99800M -23.18300M -2.50000M - -
Dividends paid - - - - -
Change to inventory - - 23.33M - -37.51400M
Change to account receivables 25.00M 175.00M -200.00000M 0.30M -0.16100M
Sale purchase of stock 71.25M - - 38.59M 250.94M
Other cashflows from financing activities 426.03M 31.29M 29.94M 37.62M 37.68M
Change to netincome - - - 110.42M 102.39M
Capital expenditures 0.91M 1.90M 9.47M 37.19M 81.70M
Change receivables - - - 0.30M -0.16100M
Cash flows other operating - - - 15.90M -5.18900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -715.80400M -245.51300M
Change in working capital 71.88M 156.27M -193.58500M 19.84M 26.86M
Stock based compensation 72.50M 86.57M 81.03M 97.95M 102.39M
Other non cash items 72.72M -38.61800M -14.04500M 12.47M 14.11M
Free cash flow -345.92800M -144.67500M -269.84500M -532.92900M 457.27M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRSP
Crispr Therapeutics AG		 0.06 0.12% 52.08 - 23.36 1518.81 2.77 84.52 14.16
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Crispr Therapeutics AG

Baarerstrasse 14, Zug, Switzerland, 6300

Key Executives

Name Title Year Born
Dr. Samarth Kulkarni Ph.D. CEO & Director 1979
Mr. Brendan Smith M.B.A. Sr. VP, CFO & Principal Accounting Officer 1976
Dr. Lawrence Otto Klein Ph.D. Chief Operating Officer 1982
Mr. James R. Kasinger Gen. Counsel & Sec. 1972
Dr. Rodger Novak M.D. Founder, Chairman & Pres 1967
Mr. Shaun Foy Founder NA
Dr. Emmanuelle Marie Charpentier Co-Founder & Scientific Advisory Board Member NA
Dr. Craig C. Mello Ph.D. Scientific Founder & Advisory Board Member NA
Dr. Chad A. Cowan Ph.D. Scientific Founder NA
Dr. Matthew Porteus M.D., Ph.D. Scientific Founder & Advisory Board Member 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.